Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma
Open Access
- 14 January 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1519777
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapies have shown promise in glioblastoma clinical studies, but responses remain inconsistent due to heterogeneous tumor antigen expression and immune evasion post-treatment. NKG2D CAR-T cells have demonstrated a favorable safety profile in patients with hematologic tumors, and showed robust antitumor efficacy in various xenograft models, including glioblastoma. However, malignant glioma cells evade immunological surveillance by reducing NKG2D ligands expression or cleavage. To enhance the effectiveness of NKG2D CAR-T therapy, we investigated the potential of combining NKG2D CAR-T with approved drugs that cross the blood-brain barrier and augment NKG2D ligands expression in glioma cells. We found that sodium valproate (VPA), an antiepileptic drug, significantly increased surface NKG2D ligands expression on glioblastoma cells at a sublethal concentration. VPA treatment enhanced the susceptibility of glioblastoma cells to NKG2D CAR-T mediated cytotoxicity in both 2D monolayer and 3D tumor spheroid models in vitro. Moreover, VPA-treated glioblastoma cells stimulated CAR-T cells to produce higher levels of inflammatory cytokines (IL-2, IFN-γ, and IL-6). Mechanistically, VPA upregulated NKG2D ligands expression via the PI3K/Akt signaling pathway. Additionally, VPA treatment augmented the antitumor activity of NKG2D CAR-T cells in a glioblastoma xenograft model in vivo. These preclinical results suggest that combining VPA with NKG2D CAR-T therapy represents a promising strategy for improving glioblastoma treatment, warranting further clinical investigation.Keywords
This publication has 36 references indexed in Scilit:
- Immunotherapy for glioblastoma: current state, challenges, and future perspectivesCellular & Molecular Immunology, 2024
- Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategiesBiomedicine & Pharmacotherapy, 2024
- CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearnNature Reviews Clinical Oncology, 2023
- CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialThe Lancet Haematology, 2023
- A natural product, Piperlongumine (PL), increases tumor cells sensitivity to NK cell killingInternational Immunopharmacology, 2021
- T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor EradicationMolecular Therapy, 2021
- Brain immunology and immunotherapy in brain tumoursNature Reviews Cancer, 2019
- Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T CellsMolecular Therapy, 2019
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoinEpilepsy Research, 1992